DETAILED ACTION

1. Claims 1-27 are pending. Claims 1 and 16-18 have been amended in this communication filed 06/09/09 entered as Response After Non-Final Action and Request for Extension of Time.

2. The 35 USC 112, First Paragraph Rejections have been overcome by Applicants' amendment and are hereby withdrawn.

3. The 35 USC 112, Second Paragraph Rejections have been overcome in view of Applicants' amendment and are hereby withdrawn.

EXAMINER'S AMENDMENT

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicants', an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given an Interview on 19 August 2009 in a telephone call to Attorney Daniel M. Cavanagh.

Claim 1. (Currently Amended) A pharmaceutical administrative system comprising: a pharmacy network including a pharmacy server and at least one pharmacy client system, the at least one pharmacy client system configured to accept and process orders for medications; and

a service center network including a service center server ~~and a service center client system,~~ the service center network coupled to the pharmacy network and configured

with a global database including a plurality of formulary records[[,]]: ~~the formulary records comprising chemical composition and properties of each of a plurality of medications,~~ wherein the service center server is configured to supply the pharmacy server at least one of the plurality of formulary records ~~comprising chemical composition and properties~~ for at least one of the orders for medication upon request by the at least one pharmacy client system when the at least one of the orders for medication is processed, and wherein the pharmacy client system is further configured to generate a medication specific label containing medication composition information.

Claim 2. (Original) The pharmaceutical administrative system of claim 1 wherein the global database further includes a plurality of order records, each order record including order information for an order accepted and processed by the at least one pharmacy client system.

Claim 3. (Original) The pharmaceutical administrative system of claim 1 wherein the global database further includes a plurality of customer records, each customer record including contact and formulary information for at least one customer.

Claim 4. (Original) The pharmaceutical administrative system of claim 2 wherein the global database further includes a plurality of patient records, each patient record including contact information and medication history for at least one patient.

Claim 5. (currently cancelled).

Claim 6. (Currently Amended) Tile pharmaceutical administrative system of claim 3 wherein the pharmacy client system is configured to provide updates to the patient, customer, and formulary records in the global database.

Claim 7. (Original) The pharmaceutical administrative system of claim 6 wherein updates to the formulary records include modification to the ingredients of the medication.

Claim 8. (Original) The pharmaceutical administrative system of claim 7 wherein updates to the modification to the ingredients of the medication include changes to amounts of caloric content in the medication.

Claim 9. (Original) The pharmaceutical administrative system of claim 7 wherein updates to the modification to the ingredients of the medication include changes to amounts and preferences of electrolytes in the medication.

Claim 10. (Original) The pharmaceutical administrative system of claim 7 wherein the pharmacy client system is configured to verify the updates to the formulary records in the global database.

Claim 11. (Original) The pharmaceutical administrative system of claim 7 wherein the medication specific label is for an intravenous solution and the medication identification information includes a refractive index associated with the intravenous solution.

Claim 12. (Original) The pharmaceutical administrative system of claim 7 wherein the medication specific label is for an intravenous solution and the medication identification information includes a level of potassium associated with the intravenous solution.

Claim 13. (Original) The pharmaceutical administrative system of claim 7 wherein the pharmacy client system is configured to generate a calcium phosphate solubility curve for an order accepted and processed by the at least one pharmacy client.

Claim 14. (Previously presented) The pharmaceutical administrative system of claim 6

further comprising:

a backup network configured to provide access to a backup database by the pharmacy network when the service center network is not available for a predetermined amount of time, the backup network comprising:

a backup server configured to:

receive replicated records of orders for medications, the replicated records of orders for medications being replicated by the service center server: and

store in the backup database the replicated records of orders for medications.

Claim 15. (Original) The pharmaceutical administrative system of claim 6 wherein the pharmacy server is configured with a local database containing a subset of formulary records of the plurality of formulary records in the global database that specifically pertains to the pharmacy network.

Claim 16. (Currently Cancelled).

Claim 17. (Currently Amended) The pharmaceutical administrative system of claim 1 wherein the medication is an intravenous solution.

Claim t8. (Currently Amended) The pharmaceutical administrative system of claim 17 wherein the pharmacy client system is configured to validate the modifications to the ingredients by generating a calcium phosphate solubility curve for the medication.

Claim 19. (Currently Amended) The pharmaceutical administrative system of claim 18 wherein the pharmacy client system is further configured to determine calcium and phosphate content in the medication and to compare the calcium and phosphate

content to the calcium phosphate solubility curve for the medication.

Claim 20. (Currently Amended) The pharmaceutical administrative system of claim 19 wherein the pharmacy client system is further configured to provide a warning when the calcium and phosphate content does not match the calcium phosphate solubility curve for the medication.

Claim 21. (Currently Amended) The pharmaceutical administrative system of claim 20 wherein the pharmacy client system is configured to generate medication specific labels for the medication.

Claim 22. (Previously presented) The pharmaceutical administrative system of claim 21 wherein the medication specific labels for the medication includes information about a refractive index of the intravenous solution.

Claim 23. (Previously presented) The pharmaceutical administrative system of claim 22 wherein the medication specific labels for the medication includes information about a level of potassium in the intravenous solution calculated using flame photometry.

Claim 24. (Previously presented) The pharmaceutical administrative system of claim 23 wherein the modifications to the ingredients of the medication includes modifications to caloric content of the medication.

Claim 25. (Currently Amended) The pharmaceutical administrative system of claim 24 wherein the pharmacy client system is configured to validate the modifications to the caloric content in the medication by comparing the modifications to predetermined amounts of caloric content in predefined medications.

Claim 26. (Previously presented) The pharmaceutical administrative system of claim 23

wherein the modifications to the ingredients of the medication includes modifications to electrolytes in the medication.

Claim 27. (Currently Amended) The pharmaceutical administrative system of claim 26 wherein the pharmacy client system is configured to validate the modifications to the electrolytes in the medication by comparing the modifications to predetermined amounts of electrolytes in predefined medications.

Claims 28-40 (Previously Cancelled).

Reasons for Allowance

Claims 1-4, 6-15, and 17-27 are allowed.

The following is an Examiner's statement of reasons: The best prior art of record is Edelson. Edelson discloses a prescription creation system which can access remote databases for presenting to the prescriber relevant authorized and current drug, drug formulary and patient history information with the creation of a transient virtual patient record. Edelson does not disclose a pharmacy client system configured to generate a medication specific label containing medication composition information.

Mayaud discloses a prescription creation system that provides patient record assembly with privacy controls for patient and doctor, adverse indication review, and access to drug information. Mayaud does not disclose a pharmacy client system configured to generate a medication specific label containing medication composition information.

Quandt discloses an automated system for the distribution of individual dosage medication. Quandt does not disclose a pharmacy client system configured to generate

a medication specific label containing medication composition information. Quandt discloses an automated system for the distribution of individual dosage medication. Shane, R; White, J.; and Saltiel, E. discloses a system that maximizes the utilization of pharmacists' interventions as part of an ongoing Drug Usage Evaluation Program. Shane, R; White, J.; and Saltiel, E. does not disclose a pharmacy client system configured to generate a medication specific label containing medication composition information.

An extensive search of the applicable prior art was done but showed no better references.

Any comments considered necessary by Applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Other Prior Art

The other prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Baum (US 4,918,604) discloses a drug labeling and prescription filing system.

Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ella Colbert whose telephone number is 571-272-6741. The examiner can normally be reached on Monday, Tuesday, and Thursday, 5:30AM-3:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dixon Thomas can be reached on 571-272-6803. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ella Colbert/
Primary Examiner, Art Unit 3696